GenomeScan is partnering with Olink Proteomics to bring proteomics to the next level by enabling high-throughput analysis of thousands of proteins, while using less than a drop of blood.
Olink’s PEA technology that is based on dual antibody recognition results in the coupling of DNA oligonucleotides and boasts exceptional levels of specificity, sensitivity and dynamic range.
By combining different omics approaches, GenomeScan helps facilitates researchers in identifying the regulators of biological processes, identifying new targets for drug discovery, evaluating therapeutic interventions, and identifying biomarkers that can be used for diagnosis, prognosis, and disease monitoring, leading to more precise and effective treatments.
Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...
24 October 2025, Over the past 20 years, Dutch hospitals have filed 559 European patent applications. This emerges from a new study by the European Patent Office and Fraunhofer...
Leiden, 24 October 2025 at 3:03 PMResearchers at LUMC, together with colleagues from the University of Florida, have identified hundreds of proteins in the blood that provide...